Press release
The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis
London
Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Market Insights
Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (58%).
USD 5.4+ billion invested by both private and public investors, since 2014
Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019. Further, there have been five instances of debt financing, accounting for more than USD 844 million in financing of RNAi therapeutics related initiatives.
Around 65 partnerships were inked since 2014
Maximum number of deals were reported in 2018. Around 30% of the deals were related to the R&D agreements; this was followed by technology licensing agreements (27%).
RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030
This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030.
To request a sample copy / brochure of this report, please visit this link
Key Questions Answered
Who are the leading industry players in this market?
What are the clinical conditions for which RNAi therapeutics are being developed?
Who are the key investors in the RNAi therapeutics market?
What kind of commercialization strategies are being adopted by RNAi therapeutics developers?
What are the different promotional and reimbursement strategies used for RNAi therapeutics?
What are the prevalent R&D trends related to RNAi therapeutics?
What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?
What kind of partnership models are used by stakeholders in this industry?
Who are the key service providers in this field of therapeutics?
How is the current and future market opportunity likely to be distributed across key market segments?
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
The USD 10 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:
Key therapeutic areas
Oncological disorders
Infectious diseases
Genetic disorders
Ophthalmic disorders
Hepatic disorders
Respiratory disorders
Type of RNAi molecule
siRNA
miRNA
shRNA
sshRNA
DNA
Route of administration
Subcutaneous
Intravenous
Intradermal
Intratumoral
Intravitreal
Oral
Intramuscular
Key geographical regions
North America
Europe
Asia Pacific and the Rest of the World
Leading Players
The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):
Amotz Shemi (Chief Executive Officer, Silenseed)
The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).
Quark Pharmaceuticals
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals
Souzhou Ribo Life Sciences
Olix Pharmaceuticals
Sirnaomics
Ariz Precision Medicine
Arrowhead Pharmaceuticals
Gradalis
Benitec Biopharma
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Gene Therapy Market (3rd Edition), 2019-2030
2. Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis here
News-ID: 2204015 • Views: …
More Releases from Roots Analysis
Microbial Fermentation CMO Market Set to Triple by 2035, Fueled by Biologics Boo …
The microbial fermentation contract manufacturing organization (CMO) market is on an exciting growth trajectory, projected to soar from USD 3.6 billion in 2024 to over USD 9.1 billion by 2035. This robust expansion, at a compound annual growth rate (CAGR) of 8.7%, reflects the rising demand for biologics and the increasing trend of outsourcing microbial fermentation processes to specialized CMOs, according to a comprehensive new report by Roots Analysis.
Why Microbial…
Peptide Synthesis Market Set to Double by 2035, Driven by Surge in Outsourcing a …
In a world where precision medicine is rapidly reshaping healthcare, the global peptide synthesis market is emerging as a quiet powerhouse. According to a comprehensive new report from Roots Analysis, the sector is poised to leap from a $2.8 billion valuation in 2024 to an impressive $5.1 billion by 2035, growing at a steady 5.5% compound annual growth rate (CAGR). This growth is fueled by a perfect storm of scientific…
Global Needles Market Set to Surpass $14.7 Billion by 2035, Fueled by Chronic Di …
In a world where chronic diseases like diabetes, cancer, and heart conditions are on the rise, the humble needle has become an unsung hero of modern medicine. According to a new report from Roots Analysis, the global needles market is poised for remarkable growth-projected to leap from $8.1 billion in 2025 to over $14.7 billion by 2035, growing at a steady 6.1% annual clip. This surge isn't just about numbers;…
ADC Contract Manufacturing Market Set to Soar, Reaching USD 6.8 Billion by 2035
In the fast-evolving world of biopharmaceuticals, the demand for precision and innovation has never been higher. Nowhere is this more evident than in the rapidly expanding market for Antibody-Drug Conjugate (ADC) contract manufacturing. According to a comprehensive new report from Roots Analysis, the global ADC contract manufacturing market is poised for remarkable growth-projected to surge from USD 1.79 billion in 2024 to over USD 6.8 billion by 2035, at a…
More Releases for RNAi
Current Trends: Antisense & RNAi Therapeutics Market in-depth Analysis
The global antisense & rnai therapeutics market is estimated to surpass $2,252.6 million by 2027, exhibiting a CAGR of 8.4% from 2020 to 2027.
The report offers a thorough analysis of global antisense & rnai therapeutics market with detailed study of various aspects of the market such as market dynamics, vital segments, major geographies, key players, and competitive landscape.
The report provides a clear picture of the current market situation and future…
RNAi Technology Market Is Witnessing Numerous Applications in Agriculture
The RNAi technologies market is witnessing numerous applications in agriculture, drug discovery, therapeutics, and medical research – specifically metabolism and functional genomics. Within the RNAi technology market, the therapeutics application segment can be further categorized as: neurology, oncology, ophthalmology, cardiology, and metabolic disorders. Based on the tools and products used for realizing Ribonucleic Acid Interference applications, the market can be classified into: libraries, software and vectors. Based on its type,…
RNAI Technology Market - Comprehensive Evaluation of Market By 2017
Transparency Market Research’s report on the Ribonucleic Acid Interference (RNAi) technologies market offers an analytical snapshot of this highly dynamic market within the pharmaceutical industry. This report provides an overview of the global RNAi technologies scenario, before detailing each critical segment-based on type, application, and products-within this market. As well as estimating market value of the RNAi technologies market in USD million, the report provides accurate market forecasts for market…
Agrow: RNAi
ReportsWorldwide has announced the addition of a new report title Agrow: RNAi to its growing collection of premium market research reports.
Employed as a research tool in entomology and as a means of crop protection and pest control, RNA interference (RNAi) technology is a natural process used to ‘silence’ genes – a way of reducing or switching off the activity (or expression) of individual genes.
With a major drive to tackle resistance…
Global RNAi Drug Pipeline Analysis
“Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. Research report covers all the ongoing drugs being developed in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in…
Global RNAI Interfering System Market Research Report 2017
Summary
RNAI Interfering System Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
The report firstly introduced the RNAI Interfering System basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes;…
